Baxter International (NYSE:BAX) Posts Earnings Results, Beats Expectations By $0.05 EPS

Baxter International (NYSE:BAX) announced its earnings results on Thursday. The medical instruments supplier reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05, FiscalAI reports. The business had revenue of $2.70 billion during the quarter, compared to analysts’ expectations of $2.62 billion. Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the company posted $0.62 EPS.

Here are the key takeaways from Baxter International’s conference call:

• Reported Q1 sales were $2.7B (+3% reported, -1% organic) and adjusted EPS fell to $0.36 from $0.55, and management is reiterating full-year guidance of $1.85–$2.05 on flat to +1% reported sales.
• The Novum LVP infusion pump remains on a ship-and-installation hold; hardware/software fixes are being finalized and may require regulatory submissions, and the company continues to factor potential customer returns into its guidance despite returns being immaterial in Q1.
• Free cash flow turned positive at $76M (vs. -$221M a year ago), and management is prioritizing debt paydown with a target of roughly 3x net leverage by end of 2026, supporting future financial flexibility.
• Management highlighted growth and innovation tailwinds — Advanced Surgery grew 10% and new product launches (Connex 360, Dynamo stretcher, IV Verify Line Labeling, XR Spine) plus Connected Care/AI initiatives are cited as drivers for back?half improvement.
• The company reiterated a full-year adjusted operating margin target of 13%–14%, expects ~500 bps of margin expansion in H2 (volume ~250 bps, cost actions ~125 bps, inventory roll-through ~125 bps), and estimates tariffs will be an ~$80M headwind for the year.

Baxter International Price Performance

NYSE:BAX traded up $0.71 during mid-day trading on Thursday, reaching $17.61. 21,191,962 shares of the company were exchanged, compared to its average volume of 6,524,775. Baxter International has a 12 month low of $15.73 and a 12 month high of $32.68. The company has a fifty day moving average of $17.92 and a 200 day moving average of $19.18. The company has a quick ratio of 1.56, a current ratio of 2.31 and a debt-to-equity ratio of 1.55. The stock has a market cap of $9.09 billion, a PE ratio of -9.52, a PEG ratio of 1.20 and a beta of 0.62.

Baxter International Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 1st. Shareholders of record on Friday, February 27th were issued a dividend of $0.01 per share. The ex-dividend date of this dividend was Friday, February 27th. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. Baxter International’s dividend payout ratio is currently -2.16%.

Institutional Investors Weigh In On Baxter International

Hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio grew its holdings in Baxter International by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 160,033 shares of the medical instruments supplier’s stock worth $3,644,000 after acquiring an additional 993 shares during the last quarter. State of Tennessee Department of Treasury boosted its stake in shares of Baxter International by 99.1% in the 4th quarter. State of Tennessee Department of Treasury now owns 111,858 shares of the medical instruments supplier’s stock valued at $2,245,000 after purchasing an additional 55,674 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of Baxter International by 5.5% in the 2nd quarter. Captrust Financial Advisors now owns 53,933 shares of the medical instruments supplier’s stock valued at $1,633,000 after purchasing an additional 2,813 shares during the last quarter. Vestor Capital LLC boosted its stake in shares of Baxter International by 1,340.3% in the 4th quarter. Vestor Capital LLC now owns 40,645 shares of the medical instruments supplier’s stock valued at $777,000 after purchasing an additional 37,823 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in shares of Baxter International in the 4th quarter valued at about $748,000. Institutional investors own 90.19% of the company’s stock.

Wall Street Analysts Forecast Growth

BAX has been the subject of a number of recent analyst reports. Citigroup dropped their target price on shares of Baxter International from $21.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. The Goldman Sachs Group dropped their target price on shares of Baxter International from $21.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, February 13th. Jefferies Financial Group dropped their target price on shares of Baxter International from $21.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, February 13th. Wall Street Zen cut shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Evercore decreased their price objective on shares of Baxter International from $23.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $19.80.

Key Stories Impacting Baxter International

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Q1 beat — Baxter reported $0.36 EPS vs. consensus $0.31 and revenue of $2.70B vs. $2.62B, a clear top?line and headline beat that spurred buying interest. Baxter Reports First-Quarter 2026 Results
• Positive Sentiment: International strength — management and reporters cited robust demand in medical products & therapies and stronger overseas sales as the driver of the beat, supporting revenue momentum outside the U.S. Baxter beats quarterly expectations on strong demand for medical devices
• Positive Sentiment: Management confirms 2026 growth view — company reiterated its growth roadmap and said it is stabilizing the business and improving execution, which reassured investors about forward plans. Baxter Posts 1Q Loss, Backs 2026 Growth Views
• Positive Sentiment: Sector tailwind and upbeat commentary — healthcare/S&P?500 index momentum and bullish analyst commentary/forecasts added supportive sentiment around the stock. Baxter Gains Strength Amid S&P 500 Index Healthcare Momentum
• Neutral Sentiment: Earnings call details available — management provided additional color on execution, margins and regional performance on the Q1 call (transcript/slides published), useful for reassessing guidance but no major surprises quoted. Baxter Q1 2026 Earnings Call Transcript
• Negative Sentiment: Margin and profitability pressure — operating margins contracted and net margin remains negative; EPS declined year?over?year (from $0.62 a year ago), signaling profit recovery still in progress. BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
• Negative Sentiment: Analyst price target cut — Evercore trimmed its price target for BAX (while keeping an Outperform rating), which could cap near?term upside despite the beat. Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.